IDSA coordinated a letter,
joined by 47 other health groups, to President-elect Trump urging that federal
efforts to combat antimicrobial resistance be maintained in the years ahead.
IDSA, SHEA, PIDS, Infection Control and Hospital Epidemiology vol. 33 no. 4 March 15, 2012 322-327.
Joint position statement of IDSA, SHEA and PIDS outlining recommendations for the mandatory implementation of antimicrobial stewardship throughout health care, including recommendations to monitor interventions and methods to address current deficiencies in education and research, as well as the lack of accurate data on antimicrobial use in the United States.
Boucher et al., Clinical Infectious Diseases vol. 48 no. 1 January 1, 2009
IDSA expresses concern about the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens.
Spellberg et al., Clinical Infectious Diseases vol. 46 no. 2 January 15, 2008 155-164.
A call to action for the medical community from the Infectious Diseases Society of America.
Dr. Andy Pavia testified on behalf of IDSA at a September 29,
2010 hearing of the Senate Labor-Health and Human Services-Education
Appropriations Subcommittee examining the Public Health Emergency Medical
Countermeasures Enterprise review recently completed by the HHS
IDSA presented testimony to a US Food and Drug Administration (FDA) panel on April 28 to address the increasingly troublesome issue of antimicrobial resistance.
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2017 Infectious Diseases Society of America